Galectin Therapeutics Inc. (GALT) Expected to Announce Earnings of -$0.14 Per Share

Equities analysts expect Galectin Therapeutics Inc. (NASDAQ:GALT) to post earnings per share (EPS) of ($0.14) for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Galectin Therapeutics’ earnings. The lowest EPS estimate is ($0.20) and the highest is ($0.08). Galectin Therapeutics posted earnings of ($0.12) per share during the same quarter last year, which indicates a negative year over year growth rate of 16.7%. The firm is scheduled to announce its next quarterly earnings report on Friday, May 10th.

On average, analysts expect that Galectin Therapeutics will report full-year earnings of ($0.58) per share for the current fiscal year, with EPS estimates ranging from ($0.74) to ($0.42). For the next financial year, analysts anticipate that the business will report earnings of ($0.55) per share, with EPS estimates ranging from ($0.58) to ($0.52). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that follow Galectin Therapeutics.

Galectin Therapeutics (NASDAQ:GALT) last posted its quarterly earnings data on Wednesday, March 6th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08).

Several research analysts have recently issued reports on GALT shares. ValuEngine upgraded shares of Galectin Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, February 14th. Zacks Investment Research upgraded shares of Galectin Therapeutics from a “hold” rating to a “buy” rating and set a $5.25 price objective on the stock in a report on Monday, March 11th. Finally, B. Riley began coverage on shares of Galectin Therapeutics in a report on Wednesday, February 13th. They set a “buy” rating and a $11.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $9.42.

In other news, Director Gilbert F. Amelio sold 30,000 shares of Galectin Therapeutics stock in a transaction dated Thursday, January 31st. The shares were sold at an average price of $5.00, for a total transaction of $150,000.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Richard E. Uihlein bought 51,500 shares of the firm’s stock in a transaction dated Tuesday, January 29th. The shares were acquired at an average price of $4.87 per share, for a total transaction of $250,805.00. Following the completion of the transaction, the director now owns 2,538,289 shares in the company, valued at approximately $12,361,467.43. The disclosure for this purchase can be found here. 45.20% of the stock is currently owned by insiders.

Several institutional investors have recently modified their holdings of the company. BlackRock Inc. boosted its position in shares of Galectin Therapeutics by 0.4% during the 4th quarter. BlackRock Inc. now owns 604,268 shares of the company’s stock valued at $2,073,000 after acquiring an additional 2,611 shares in the last quarter. MML Investors Services LLC boosted its position in shares of Galectin Therapeutics by 55.8% during the 4th quarter. MML Investors Services LLC now owns 26,926 shares of the company’s stock valued at $92,000 after acquiring an additional 9,642 shares in the last quarter. Stratos Wealth Partners LTD. boosted its position in shares of Galectin Therapeutics by 45.5% during the 4th quarter. Stratos Wealth Partners LTD. now owns 40,950 shares of the company’s stock valued at $140,000 after acquiring an additional 12,796 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Galectin Therapeutics by 7.3% during the 4th quarter. Geode Capital Management LLC now owns 227,175 shares of the company’s stock valued at $779,000 after acquiring an additional 15,410 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of Galectin Therapeutics during the 3rd quarter valued at about $107,000. Institutional investors and hedge funds own 12.58% of the company’s stock.

Shares of NASDAQ:GALT traded up $0.30 on Friday, hitting $5.11. 501,365 shares of the company were exchanged, compared to its average volume of 404,262. Galectin Therapeutics has a one year low of $3.10 and a one year high of $9.49. The company has a market cap of $219.10 million, a price-to-earnings ratio of -13.45 and a beta of 3.70.

Galectin Therapeutics Company Profile

Galectin Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease, skin disease, and cancer. The company's lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer.

Featured Story: Call Option Volume

Get a free copy of the Zacks research report on Galectin Therapeutics (GALT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Galectin Therapeutics (NASDAQ:GALT)

Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.